Trimodality Approach for Esophageal Malignancies

Ammara A Watkins; Jessica A Zerillo; Michael S Kent

doi:10.1016/j.suc.2021.03.007

Trimodality Approach for Esophageal Malignancies

Surg Clin North Am. 2021 Jun;101(3):453-465. doi: 10.1016/j.suc.2021.03.007.

Authors

Ammara A Watkins¹, Jessica A Zerillo², Michael S Kent³

Affiliations

¹ Division of Thoracic Surgery and Interventional Pulmonology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Boston, MA 02215, USA.
² Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Shapiro 9, Boston, MA 02215, USA.
³ Division of Thoracic Surgery and Interventional Pulmonology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Boston, MA 02215, USA. Electronic address: mkent@bidmc.harvard.edu.

PMID: 34048765
DOI: 10.1016/j.suc.2021.03.007

Abstract

Trimodality therapy, or the use of concurrent chemoradiation followed by surgery, is the cornerstone of contemporary management of esophageal cancer. This article discusses the landmark trials and most current data to understand the concepts, applications, and outcomes from trimodality therapy in locally advanced esophageal cancer.

Keywords: Chemoradiation; Esophageal cancer; Neoadjuvant; Trimodality therapy.

Publication types

Review

MeSH terms

Adenocarcinoma / therapy*
Carcinoma, Squamous Cell / therapy*
Chemoradiotherapy, Adjuvant*
Esophageal Neoplasms / therapy*
Esophagectomy*
Humans
Neoadjuvant Therapy*
Treatment Outcome